Hydromorphone Dosing Guidelines

Opioid-Naïve Adults

For opioid-naïve adults, initiate oral hydromorphone at 2–4 mg every 4–6 hours, or start parenteral hydromorphone at 1–2 mg subcutaneously/IV every 2–4 hours. 1

Oral Dosing for Opioid-Naïve Patients

Starting dose: 2–4 mg orally every 4–6 hours 1
Conservative approach: When converting from other opioids, administer half of the usual starting dose every 4–6 hours to minimize overdose risk 1
Duration of action: 2–3 hours for immediate-release formulations 2

Parenteral Dosing for Opioid-Naïve Patients

Starting dose: 1–2 mg subcutaneously or IV every 2–4 hours as needed 3
For continuous infusion: Start at 10 mg over 24 hours via syringe driver if frequent dosing (more than twice daily) is needed 3
Breakthrough dosing: 5–15% of total daily dose may be administered every 2 hours as needed 1

Opioid-Tolerant Adults

For patients already taking opioids, calculate the equianalgesic dose and reduce by 25–50% to account for incomplete cross-tolerance. 2, 4, 5

Conversion from Morphine to Hydromorphone

Standard ratio: 10 mg morphine (IV/oral) = 1.5 mg hydromorphone (IV/oral), approximately a 6.7:1 ratio 2, 5
Mandatory dose reduction: Reduce the calculated equianalgesic dose by 25–50% when rotating from morphine to hydromorphone 2, 4, 5
Example: A patient on 192 mg/day IV morphine converts to approximately 28.8 mg/day IV hydromorphone, then reduce by 50% to 14.4 mg/day (0.6 mg/hour continuous infusion) 4, 5

Alternative Conversion Ratios

Oral morphine to oral hydromorphone: 30 mg oral morphine = 7.5 mg oral hydromorphone (factor of 2.5–5) 2
IV to oral hydromorphone: 1 mg IV hydromorphone = 2.5 mg oral hydromorphone 5, 6
IV hydromorphone to oral morphine equivalent: 1 mg IV hydromorphone = 11.46 mg oral morphine equivalent daily dose (MEDD) 6

Titration for Opioid-Tolerant Patients

If pain was well-controlled: Use 50–75% of calculated equianalgesic dose 2, 4, 5
If pain was poorly controlled: May use 100% of equianalgesic dose or increase by up to 25% 2, 4
Rescue doses: Each immediate-release dose should equal 10% of the total daily opioid dose 7
Frequency: Patients may take rescue doses every hour for up to 4 hours before consulting a physician 7

Elderly Patients (≥65 Years)

Elderly patients require dose reductions of 25–50% from standard adult doses due to increased sensitivity to opioids and higher risk of respiratory depression. 8, 1

Specific Considerations for Elderly

Starting dose: Use the lower end of the dosing range (2 mg oral or 0.5–1 mg parenteral) 8, 1
Formulations with lower doses: Consider hydromorphone 2.5 mg/acetaminophen 325 mg to facilitate cautious dosing 8
Monitoring: Elderly patients have increased risk of respiratory depression and require close monitoring for CNS and respiratory effects 1
Renal considerations: Elderly patients are more likely to have decreased renal function; hydromorphone is substantially excreted by the kidney 1

Pediatric Patients

Continuous infusion hydromorphone in mechanically ventilated children typically starts at 0.024 mg/kg/hour, with maximum doses around 0.05 mg/kg/hour. 9

Pediatric Dosing Parameters

Starting dose: 0.024 ± 0.04 mg/kg/hour for continuous infusion 9
Maximum dose: 0.05 ± 0.1 mg/kg/hour 9
Duration: Average therapy duration is 182 ± 169 hours 9
ECMO patients: Require significantly higher initial and maximum doses compared to non-ECMO patients 9
Efficacy: Most mean daily pain scores (66%) were below 1 on the FLACC scale, indicating adequate pain control 9

Important Pediatric Caveat

Safety not established: The FDA label states that safety and effectiveness in pediatric patients have not been formally established 1
Adjunctive therapy: Hydromorphone is typically used as an adjunctive analgesic alongside other pain and sedation medications 9

Special Populations

Renal Impairment

Start at one-fourth to one-half the usual dose in patients with renal impairment. 1

Rationale: Hydromorphone is substantially excreted by the kidney; severe renal impairment prolongs terminal elimination half-life 1
Monitoring: Close monitoring during dose titration is mandatory 1
Alternative consideration: When eGFR <30 mL/min, consider using oxycodone instead of morphine (though this applies to morphine, not hydromorphone directly) 3
Caution with metabolites: Unlike morphine, hydromorphone has less concern for accumulation of toxic metabolites in renal failure 2

Hepatic Impairment

Start at one-fourth to one-half the usual dose depending on degree of hepatic dysfunction. 1

Pharmacokinetic changes: Increased Cmax and AUC occur with hepatic impairment 1
Severe hepatic impairment: Has not been studied; expect further increases in exposure 1
Titration: Close monitoring during dose titration is essential 1

Critical Dosing Principles

Starting Low and Titrating

Lowest effective dose: Always start at the lowest possible effective dosage for the shortest duration 8, 1
Avoid rapid increases: Rapid dosage increases put patients at greater risk for sedation, respiratory depression, and overdose 8
No upper limit: There is no ceiling dose for pure agonist opioids like hydromorphone as long as side effects can be controlled 7

Monitoring Requirements

First 24–72 hours: Monitor closely for respiratory depression, especially after initiation or dose increases 1
Daily assessment: During initial titration, at least once-daily assessment is necessary to judge analgesic efficacy and detect side effects 7
Continuous reevaluation: Assess maintenance of pain control, adverse reactions, and development of addiction, abuse, or misuse 1

Breakthrough Pain Management

Chronic pain: For around-the-clock dosing, a supplemental dose of 5–15% of total daily usage may be given every 2 hours as needed 1
Cancer pain: Each rescue dose should equal 10% of the daily sustained-release opioid dose 7

Discontinuation

When discontinuing hydromorphone, taper the dose gradually by 25–50% every 2–4 days while monitoring for withdrawal symptoms. 1

Tapering Protocol

Never stop abruptly: Abrupt discontinuation can precipitate withdrawal in physically dependent patients 7, 1
Reduction schedule: Decrease by 25–50% every 2–4 days 1
Alternative schedule: For longer-term use, dose reduction in steps of 30–50% over about a week may be appropriate 7
Monitor for: Reappearance of pain and development of withdrawal symptoms 7, 1
If withdrawal occurs: Raise the dose to the previous level and taper more slowly by increasing the interval between decreases or decreasing the amount of change 1

Common Pitfalls and Caveats

Conversion Errors

Never apply MME directly: Do not use calculated morphine milligram equivalents (MME) directly for opioid rotation without the mandatory 25–50% reduction for incomplete cross-tolerance 5
High inter-individual variability: Pharmacokinetics vary substantially (9–31% coefficient of variation); always titrate to effect regardless of calculated conversions 5
Conservative approach: It is safer to underestimate a patient's 24-hour hydromorphone dosage than to overestimate and manage an overdose 1

Specific Clinical Contexts

Cancer pain with morphine intolerance: Hydromorphone is indicated when there is resistance or intolerance to morphine 7
Renal failure advantage: Prefer hydromorphone over morphine in renal failure to avoid accumulation of morphine-6-glucuronide 2
ECMO patients: Require significantly higher doses due to drug sequestration by the lipophilic circuit 9, 10
Abuse liability: IV hydromorphone has potent euphoric effects and significant abuse potential; use caution in patients with substance use history 11

Concomitant Medications

Antiemetics: Consider concomitant use of an antiemetic (such as haloperidol) when starting opioids 3
Laxatives: Prescribe a regular stimulant laxative (such as senna) to prevent opioid-induced constipation 3
Acetaminophen limits: Monitor cumulative acetaminophen doses in combination products (maximum 325 mg per dosage unit per FDA) 2, 8

What are the recommended hydromorphone dosing guidelines for adults (opioid‑naïve and opioid‑tolerant), elderly patients, and children?

Have a follow-up question?